Kanabidiol (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Kanabidiol" in Serbian language version.

refsWebsite

Global rank Serbian rank

9nih.gov

4^th place

8^th place

9doi.org

2^nd place

4^th place

4web.archive.org

1^st place

1dea.gov

8,191^st place

low place

1cannabis-med.org

low place

1unodc.org

2,494^th place

1,775^th place

1archive.org

6^th place

5^th place

1worldcat.org

5^th place

12^th place

1wkhealth.com

low place

3,674^th place

1wiley.com

222^nd place

155^th place

1scielo.br

1,606^th place

4,107^th place

1druglibrary.org

low place

1hempembassy.it

low place

1globenewswire.com

2,614^th place

low place

archive.org

Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology. 72 (4): 649—56. PMC 2071638 . PMID 6269680.

cannabis-med.org

McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08. Архивирано из оригинала (PDF) 22. 06. 2017. г. Приступљено 05. 01. 2017.

dea.gov

DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml Архивирано на сајту Wayback Machine (17. јануар 2017); Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").

doi.org

Mechoulam R, Parker LA, Gallily R (2002). „Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol (Review). 42 (11 Suppl): 11S—19S. PMID 12412831. doi:10.1177/0091270002238789.
Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). „Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res (Review). 23 (5): 597—602. PMID 18844286. doi:10.1002/ptr.2625.
McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08. Архивирано из оригинала (PDF) 22. 06. 2017. г. Приступљено 05. 01. 2017.
Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) 18. 07. 2011. г. Приступљено 3. 5. 2007.
Mechoulam, R.; M. Peters; Murillo-Rodriguez (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. ^{[мртва веза]}
Zuardi, A.W; J.A.S. Crippa; et al. (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001.
Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience. 30 (4): 277—282. PMID 3793381. doi:10.3109/00207458608985678.
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. (децембар 2019). „Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry. 6 (12): 995—1010. PMC 6949116 . PMID 31672337. doi:10.1016/S2215-0366(19)30401-8.
VanDolah HJ, Bauer BA, Mauck KF (септембар 2019). „Clinicians' Guide to Cannabidiol and Hemp Oils”. Mayo Clinic Proceedings. 94 (9): 1840—1851. PMID 31447137. doi:10.1016/j.mayocp.2019.01.003 .

druglibrary.org

Snider, Stuart R.; Consroe, Paul (1985). „Beneficial and Adverse Effects of Cannabidiol in a Parkinson Patient with Sinemet-Induced Dystonic Dyskinesia”. Neurology (Suppl 1): 201.

globenewswire.com

„CBD (Cannabidiol) Market Size to Reach USD 47.22 Billion by 2028 - Increased Demand for CBD (Cannabidiol) for Health and Wellness Purposes to Drive Market”. Global Newswire. 8. 2. 2022. Архивирано из оригинала 20. 6. 2022. г. Приступљено 20. 6. 2022.

hempembassy.it

„THC e CBD”. hempembassy.it. 2023-04-23.

nih.gov

ncbi.nlm.nih.gov

Mechoulam R, Parker LA, Gallily R (2002). „Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol (Review). 42 (11 Suppl): 11S—19S. PMID 12412831. doi:10.1177/0091270002238789.
Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). „Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res (Review). 23 (5): 597—602. PMID 18844286. doi:10.1002/ptr.2625.
Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology. 72 (4): 649—56. PMC 2071638 . PMID 6269680.
Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) 18. 07. 2011. г. Приступљено 3. 5. 2007.
Mechoulam, R.; M. Peters; Murillo-Rodriguez (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. ^{[мртва веза]}
Zuardi, A.W; J.A.S. Crippa; et al. (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001.
Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience. 30 (4): 277—282. PMID 3793381. doi:10.3109/00207458608985678.
Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, et al. (децембар 2019). „Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis”. The Lancet. Psychiatry. 6 (12): 995—1010. PMC 6949116 . PMID 31672337. doi:10.1016/S2215-0366(19)30401-8.
VanDolah HJ, Bauer BA, Mauck KF (септембар 2019). „Clinicians' Guide to Cannabidiol and Hemp Oils”. Mayo Clinic Proceedings. 94 (9): 1840—1851. PMID 31447137. doi:10.1016/j.mayocp.2019.01.003 .

scielo.br

Zuardi, A.W; J.A.S. Crippa; et al. (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001.

unodc.org

Grlić, Ljubiša (1962). „A comparative study on some chemical and biological characteristics of various samples of cannabis resin”. Bulletin on Narcotics. United Nations Office on Drugs and Crime (3): 37—46.

web.archive.org

DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml Архивирано на сајту Wayback Machine (17. јануар 2017); Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").
McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08. Архивирано из оригинала (PDF) 22. 06. 2017. г. Приступљено 05. 01. 2017.
Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) 18. 07. 2011. г. Приступљено 3. 5. 2007.
„CBD (Cannabidiol) Market Size to Reach USD 47.22 Billion by 2028 - Increased Demand for CBD (Cannabidiol) for Health and Wellness Purposes to Drive Market”. Global Newswire. 8. 2. 2022. Архивирано из оригинала 20. 6. 2022. г. Приступљено 20. 6. 2022.

wiley.com

www3.interscience.wiley.com

Mechoulam, R.; M. Peters; Murillo-Rodriguez (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. ^{[мртва веза]}

wkhealth.com

meta.wkhealth.com

Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) 18. 07. 2011. г. Приступљено 3. 5. 2007.

worldcat.org

Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) 18. 07. 2011. г. Приступљено 3. 5. 2007.